CSA Medical said today that the first patient was treated using the company’s new rapid AV spray catheter for the management of persistent symptomatic esophageal cancer and associated dysplastic Barrett’s disease.
The device uses a stainless steel catheter wall to cut the time needed to deliver liquid nitrogen spray to the treatment site by 50%, the company said. It was recently cleared for use with CSA Medical’s truFreeze system – a cryosurgical tool used to ablate benign and malignant lesions.
The first patient was treated at the University of Rochester Medical Center by Dr. Vivek Kaul, the company noted.
“With a significantly reduced time to ‘spray actuation’ and a uniform, non-dissipating freeze pattern, we found the Rapid AV catheter to work reliably, consistently and effectively in a diverse array of clinical settings, from flat Barrett’s ablation to bulky tumor palliation,” Kaul said in prepared remarks.
“This product expansion solidifies truFreeze liquid nitrogen spray cryotherapy as the only ablation solution for the full range of Barrett’s Esophagus disease as well as esophageal cancer,” president & CEO Dr. Ellen Sheets added.
